We Claim:

1. A pharmaceutical composition comprising a combination of an antibody specific for CD38 which cross-competes with an antibody comprising an HCDR1 of sequence GFTFSSYYMN (SEQ ID NO: 1), HCDR2 of sequence GISGDPSNTYYADSVKG (SEQ ID NO: 2), HCDR3 of sequence DLPLVYTGFAY (SEQ ID NO: 3), LCDR1 of sequence SGDNLRHYYVY (SEQ ID NO: 4), LCDR2 of sequence GDSKRPS (SEQ ID NO: 5), and LCDR3 of sequence QTYTGGASL (SEQ ID NO: 6) and melphalan for the treatment of multiple myeloma.

2. A pharmaceutical composition according to claim 1, wherein the antibody comprises an HCDR1 of sequence GFTFSSYYMN (SEQ ID NO: 1), HCDR2 of sequence GISGDPSNTYYADSVKG (SEQ ID NO: 2), HCDR3 of sequence DLPLVYTGFAY (SEQ ID NO: 3), LCDR1 of sequence SGDNLRHYYVY (SEQ ID NO: 4), LCDR2 of sequence GDSKRPS (SEQ ID NO: 5), and LCDR3 of sequence QTYTGGASL (SEQ ID NO: 6).

3. A pharmaceutical composition according to claim 2, wherein the antibody comprises a variable heavy chain of the sequence QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSN TYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQG TLVTVSS (SEQ ID NO: 7) and a variable light chain of the sequence DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPE RFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 9).

4. A pharmaceutical composition according to any one of the preceeding claims, wherein the antibody specific for CD38 and melphalan are administered separately.

5. A pharmaceutical composition according to claim 4, wherein melphalan is administered prior to administration of the antibody specific for CD38.

6. A pharmaceutical composition according to claim 8, wherein melphalan is administered 72 hours prior to administration of the antibody specific for CD38.

7. A method of treating multiple myeloma in an individual in need thereof, which comprises administration of an antibody specific for CD38 which cross-competes with an antibody comprising an HCDR1 of sequence GFTFSSYYMN (SEQ ID NO: 1), HCDR2 of sequence GISGDPSNTYYADSVKG (SEQ ID NO: 2), HCDR3 of sequence DLPLVYTGFAY (SEQ ID NO: 3), LCDR1 of sequence SGDNLRHYYVY (SEQ ID NO: 4), LCDR2 of sequence GDSKRPS (SEQ ID NO: 5), and LCDR3 of sequence QTYTGGASL (SEQ ID NO: 6) and melphalan to an individual having multiple myeloma.

8. The method according to claim 7, wherein the antibody specific for CD38 comprises an HCDR1 of sequence GFTFSSYYMN (SEQ ID NO: 1), HCDR2 of sequence GISGDPSNTYYADSVKG (SEQ ID NO: 2), HCDR3 of sequence DLPLVYTGFAY (SEQ ID NO: 3), LCDR1 of sequence SGDNLRHYYVY (SEQ ID NO: 4), LCDR2 of sequence GDSKRPS (SEQ ID NO: 5), and LCDR3 of sequence QTYTGGASL (SEQ ID NO: 6).

Claims:

1. A pharmaceutical composition comprising a combination of (i) an antibody specific for CD38 comprising an HCDR1 of sequence GFTFSSYYMN (SEQ ID NO: 1), HCDR2 of sequence GISGDPSNTYYADSVKG (SEQ ID NO: 2), HCDR3 of sequence DLPLVYTGFAY (SEQ ID NO: 3), LCDR1 of sequence SGDNLRHYYVY (SEQ ID NO: 4), LCDR2 of sequence GDSKRPS (SEQ ID NO: 5), and LCDR3 of sequence QTYTGGASL (SEQ ID NO: 6) and (ii) melphalan for the treatment of multiple myeloma.

2. A pharmaceutical composition according to claim 1, wherein the antibody comprises a variable heavy chain of the sequence:

(SEQ ID NO: 7)

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEW

VSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY

YCARDLPLVYTGFAYWGQGTLVTVSS;

and a variable light chain of the sequence:

(SEQ ID NO: 9)

DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVI

YGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGA

SLVFGGGTKLTVLGQ.

3. A pharmaceutical composition according to claim 1, wherein the antibody specific for CD38 and melphalan are administered separately.

4. A pharmaceutical composition according to claim 3, wherein melphalan is administered prior to administration of the antibody specific for CD38.

5. A pharmaceutical composition according to claim 4, wherein melphalan is administered 72 hours prior to administration of the antibody specific for CD38.

6. A pharmaceutical composition according to claim 2, wherein the antibody specific for CD38 and melphalan are administered separately.

7. A pharmaceutical composition according to claim 6, wherein melphalan is administered prior to administration of the antibody specific for CD38.

8. A pharmaceutical composition according to claim 7, wherein melphalan is administered 72 hours prior to administration of the antibody specific for CD38.